Clinical Trials Browser

Not yet recruiting × pembrolizumab × Head & Neck × Clear all

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07552558 2026-04-27

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Jaw Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Tongue Neoplasms

NCT07513324 2026-04-07

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Phase 2 Not yet recruiting

116 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07509099 2026-04-03

Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

Phase 3 Not yet recruiting

316 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07129772 2025-09-04

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

53 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT07010393 2025-06-08

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Phase 4 Not yet recruiting

335 enrolled

Head & Neck

Thyroid Neoplasms

NCT06894459 2025-04-30

A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

Phase 2 Not yet recruiting

180 enrolled

Head & Neck

Head and Neck Neoplasms

NCT06814067 2025-02-07

Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Not yet recruiting

80 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06793761 2025-01-27

A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC

Phase 2 Not yet recruiting

260 enrolled

Head & Neck

Head and Neck Neoplasms

Clinical Trials

NEO COMBAT XL

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC